Marta Olejniczak

Head

Institute of Bioorganic Chemistry PAS

Poland

Research Interests

Explore related searches

Professors in Poland

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Marta Olejniczak is the Head of the Institute of Bioorganic Chemistry PAS in Poland. Her research focuses on the applications of CRISPR genome editing, RNA regulation, and the development of artificial miRNAs, particularly in the context of polyglutamine diseases such as Huntington's disease. Dr. Olejniczak's recent publications include studies on CRISPR/Cas9-induced DNA modifications and their therapeutic implications for genetic disorders.

Articles (10)

Year:

2024

Year:

2023

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Collaborators (5)

Magdalena Woźna-Wysocka

Institute of Bioorganic Chemistry

POLAND

View details

ADAM CIESIOŁKA

Institute of Organic Chemistry, Polish Academy of Sciences

POLAND

View details

Maciej Figiel

head of department, principal investigator

Institute of Bioorganic Chemistry Polish Academy of Sciences

POLAND

View details

Anna Kotowska-Zimmer

Institute of Bioorganic Chemistry PAS

POLAND

View details

Emilia Kozłowska

Institute of Bioorganic Chemistry Polish Academy of Sciences

POLAND

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Marta Olejniczak

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

CRISPR/Cas9-induced double-strand breaks in the huntingtin locus lead to CAG repeat contraction through DNA end resection and homology-mediated repair

RNA regulation in brain function and disease 2022 (NeuroRNA): A conference report.

A CAG repeat-targeting artificial miRNA lowers the mutant huntingtin level in the YAC128 model of Huntington’s disease

Advances in Modeling Polyglutamine Diseases Using Genome Editing Tools

Artificial miRNAs as therapeutic tools: Challenges and opportunities

Paving the way towards precise and safe CRISPR genome editing.

Artificial miRNAs targeting CAG repeat expansion in ORFs cause rapid deadenylation and translation inhibition of mutant transcripts

Universal RNAi Triggers for the Specific Inhibition of Mutant Huntingtin, Atrophin-1, Ataxin-3, and Ataxin-7 Expression

Computational Tools and Resources Supporting CRISPR-Cas Experiments

Generation of New Isogenic Models of Huntington’s Disease Using CRISPR-Cas9 Technology

Collaborators (5)

Magdalena Woźna-Wysocka

ADAM CIESIOŁKA

Maciej Figiel

Anna Kotowska-Zimmer

Emilia Kozłowska

Make your next move.